Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer.
Reads0
Chats0
TLDR
Comparing the outcomes from three prospective multicenter studies investigating the use of CTC to monitor patients undergoing treatment for metastatic breast, colorectal, or prostate cancer is compared and the CTC definition used in these studies is reviewed.Abstract:
The increasing number of treatment options for patients with metastatic carcinomas has created a concomitant need for new methods to monitor their use. Ideally, these modalities would be noninvasive, be independent of treatment, and provide quantitative real-time analysis of tumor activity in a variety of carcinomas. Assessment of circulating tumor cells (CTCs) shed into the blood during metastasis may satisfy this need. We developed the CellSearch System to enumerate CTC from 7.5 mL of venous blood. In this review we compare the outcomes from three prospective multicenter studies investigating the use of CTC to monitor patients undergoing treatment for metastatic breast (MBC), colorectal (MCRC), or prostate cancer (MPC) and review the CTC definition used in these studies. Evaluation of CTC at anytime during the course of disease allows assessment of patient prognosis and is predictive of overall survival.read more
Citations
More filters
Journal ArticleDOI
Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
Agustí Barnadas,Luis Manso,Concepción de la Piedra,Cristina Meseguer,C. Crespo,Patricia Gómez,Lourdes Calvo,Purificación Martínez,Manuel Ruiz-Borrego,Antonia Perelló,Antonio Antón,Manuel Codes,Mireia Margeli,A Murias,Javier Salvador,Miguel Ángel Seguí,Ana de Juan,Joaquín Gavilá,M. Luque,Diego Pérez,Pilar Zamora,Alberto Arizcuma,Jose Ignacio Chacon,Lucía Heras,Marta Martín-Fernández,Ignacio Mahillo-Fernández,Ignacio Tusquets +26 more
TL;DR: Baseline levels of NTX, BSAP and CTCs, and changes after treatment initiation with bisphosphonates, may be useful for the prognostic assessment of patients with bone metastatic breast cancer.
Journal ArticleDOI
Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?
Filippo Pelizzaro,Romilda Cardin,B. Penzo,Elisa Pinto,Alessandro Vitale,Umberto Cillo,Francesco Paolo Russo,Fabio Farinati +7 more
TL;DR: In this article, a comprehensive overview on the most relevant available evidence on novel circulating biomarkers for early diagnosis, prognostic stratification, and therapeutic monitoring is provided for hepatocellular carcinoma (HCC) patients.
Journal ArticleDOI
High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients
Dagnija Kalniete,Miki Nakazawa-Miklasevica,Ilze Strumfa,Arnis Āboliņš,Arvīds Irmejs,Jānis Gardovskis,Edvīns Miklaševičs +6 more
TL;DR: The finding suggests that miR-214 possibly could be used as a potential prognostic biomarker for triple-negative breast cancer patients and shows significantly higher expression level in sporadic tissues than in hereditary ones.
Journal ArticleDOI
The advantage of circulating tumor cells over serum carcinoembryonic antigen for predicting treatment responses in rectal cancer
Wenjie Sun,Ting Huang,Guichao Li,Weiqi Shen,Ji Zhu,Qinghui Jin,Jianlong Zhao,Chunping Jia,Zhen Zhang +8 more
TL;DR: CTCs are promising markers for the evaluation and prediction of treatment responses in rectal cancer patients, superior to the conventional tumor marker CEA.
Journal ArticleDOI
Antibody-drug conjugates targeting prostate-specific membrane antigen.
TL;DR: The preclinical and clinical findings have largely substantiated the promise of PSMA as an ADC target and potential future directions for ADCs that target PSMA are summarized.
References
More filters
Journal ArticleDOI
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited
TL;DR: It is now known that the potential of a tumour cell to metastasize depends on its interactions with the homeostatic factors that promote tumour-cell growth, survival, angiogenesis, invasion and metastasis.
Journal ArticleDOI
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Journal ArticleDOI
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Sunitha Nagrath,Lecia V. Sequist,Shyamala Maheswaran,Daphne W. Bell,Daphne W. Bell,Daniel Irimia,Lindsey Ulkus,Matthew R. Smith,Eunice L. Kwak,Subba R. Digumarthy,Alona Muzikansky,Paula D. Ryan,Ulysses J. Balis,Ulysses J. Balis,Ronald G. Tompkins,Daniel A. Haber,Mehmet Toner +16 more
TL;DR: The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 samples, with a range of 5–1,281CTCs per ml and approximately 50% purity.
Journal ArticleDOI
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
W. Jeffrey Allard,Jeri Matera,M. Craig Miller,Madeline Repollet,Mark Connelly,Chandra Rao,Arjan G.J. Tibbe,Jonathan W. Uhr,Leon W.M.M. Terstappen +8 more
TL;DR: The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs, which are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.
Journal ArticleDOI
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono,Howard I. Scher,R. Bruce Montgomery,Chris Parker,M. Craig Miller,H. Tissing,Gerald V. Doyle,Leon W.W.M. Terstappen,Kenneth J. Pienta,Derek Raghavan +9 more
TL;DR: CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.